Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a BTK inhibitor, targets BCR signaling and is particularly active in lymphomas with BCR and MYD88 mutations. We performed a proof of concept phase Ib study of ibrutinib monoth...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Cell
Autores principales: Lionakis, Michail S., Dunleavy, Kieron, Roschewski, Mark, Widemann, Brigitte C., Butman, John A., Schmitz, Roland, Cole, Diane E., Melani, Christopher, Higham, Christine S., Desai, Jigar V., Ceribelli, Michele, Chen, Lu, Thomas, Craig J., Little, Richard F., Gea-Banacloche, Juan, Bhaumik, Sucharita, Stetler-Stevenson, Maryalice, Pittaluga, Stefania, Jaffe, Elaine S., Heiss, John, Lucas, Nicole, Steinberg, Seth M., Staudt, Louis M., Wilson, Wyndham H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571650/
https://ncbi.nlm.nih.gov/pubmed/28552327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2017.04.012
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares